1. Metabolic Enzyme/Protease
  2. CETP

Evacetrapib (Synonyms: LY2484595)

Cat. No.: HY-13327 Purity: 98.18%
Data Sheet SDS Handling Instructions

Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.

For research use only. We do not sell to patients.
Evacetrapib Chemical Structure

Evacetrapib Chemical Structure

CAS No. : 1186486-62-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO $211 In-stock
5 mg $150 In-stock
10 mg $240 In-stock
50 mg $750 In-stock
100 mg $1250 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    Evacetrapib purchased from MCE. Usage Cited in: Atherosclerosis. 2014 Aug;235(2):449-62.

    Downregulation of SREBP2-M by EVA and TOR reduced LDLR and PCSK9 expression. HepG2 cells are treated with EVA at indicated concentrations for 24 h. Total cell lysates (30 µg) are analyzed for the protein abundance of LDLR and β-actin. Nuclear and cytoplasmic extracts are isolated from each sample. Nuclear extracts of 30 µg protein per sample are used to detect SREBP2-M. The membrane is reprobed with anti-HDAC1. Cytoplasmic extracts of 30 µg protein per sample are used to detect SREBP2-P. The mem

    Featured Recommendations

    Related Screening Libraries:

    Related Small Molecules:

    View MoreCollapse
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.

    IC50 & Target

    IC50: 5.5 nM (CETP)[1]

    In Vitro

    Evacetrapib is a novel benzazepine-based CETP inhibitor. In the buffer CETP assay, the absolute potency of the compound is 5.5 nM. In the human plasma CETP assay, the CETP concentration is about 2 μg/mL (25 nM) and the 36 nM IC50 value again indicates that Evacetrapib is a potent CETP inhibitor against either the recombinant protein or CETP from human plasma. Evacetrapib is apparently much more potent than Dalcetrapib[1].

    In Vivo

    In double transgenic mice expressing human CETP and apoAI, Evacetrapib exhibits an ex vivo CETP inhibition ED50 of less than 5 mg/kg at 8 h post oral dose and significantly elevated HDL cholesterol. Importantly, no blood pressure elevation is observed in rats dosed with Evacetrapib at high exposure multiples compared with the positive control, torcetrapib. Evacetrapib administered orally at 30 mg/kg results in 98.4%, 98.6%, and 18.4% inhibition of CETP activity at 4, 8 and 24 h post dose respectively. Evacetrapib dosed orally at 30 mg/kg resulted in 129.7% increase in HDL-C 8 h after oral administration[1].

    Clinical Trial
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.5658 mL 7.8290 mL 15.6580 mL
    5 mM 0.3132 mL 1.5658 mL 3.1316 mL
    10 mM 0.1566 mL 0.7829 mL 1.5658 mL
    Please refer to the solubility information to select the appropriate solvent.
    Kinase Assay
    [1]

    Human CETP cDNA is amplified from a human liver cDNA library and the sequence is confirmed to be identical to the published sequence. The cDNA is subcloned into a pcDNA3.1 vector, under the control of CMV promoter. A stable line is established in CV1 cells in which the above-mentioned construct is used to express the recombinant human CETP. The medium contained the secreted recombinant CETP protein and the amount (19 ng/μL) is quantified by an ELISA kit. The medium is then aliquoted in 0.2% BSA and stored at -80°C. The stock CETP protein is diluted 150-fold in CETP buffer (10 mM Tris, 150 mM NaCl, and 2 mM EDTA) before use. The assay is set up in a 96-well plate. Each well received 97.5 μL diluted CETP protein (final concentration 7 nM) and 2.5 μL of compound stock. After a 30 min incubation at 37°C, 5 μL of substrate stock (the same stock used in the human plasma CETP assay), 0.16 μL of VLDL stock (2.5 mg/mL, Intracel) and 145 μL of CETP buffer are added, and the incubation is continued for another 4 h. Signal is read for the human plasma CETP assay[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Evacetrapib is prepared in 10% acacia (Rat)[1].

    Rat[1]
    The blood pressure study is carried out using telemetered, male, obese Zucker Diabetic rats (ZDF fa/fa rats, 8 weeks of age on arrival; n=4). All rats underwent surgical implantation of a telemetry transmitter for continuous monitoring of hemodynamic parameters throughout the study. The rats are acclimated on Purina 5008 chow and house water ad libitum until 11 weeks of age. Mean daily blood pressure for the 24-h period immediately prior to administration of compound is taken as the baseline blood pressure. On the day of an experiment, a single 160 mg/kg dose (in 10% acacia) of Evacetrapib as the lysine salt is administered by oral gavage, and the drug effect is taken as the average daily mean arterial pressure (MAP) during the 24 h period following the dose. Data are expressed as the change in MAP from baseline. Following the last day of blood pressure monitoring, samples are collected from the orbital sinus at 1, 2, 4, 8, and 24 h post dose into tubes containing EDTA and processed into plasma. Plasma concentrations of Evacetrapib are measured using liquid chromatography tandem mass spectrometry. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    638.65

    Formula

    C₃₁H₃₆F₆N₆O₂

    CAS No.

    1186486-62-3

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Evacetrapib
    Cat. No.:
    HY-13327
    Quantity: